Reozalimab
Reozalimab is a bispecific antibody targeting to PD-1/PD-L1. Reozalimab mediates antibody-dependent cell cytotoxicity in cancer research[1][2].
Product Specifications
CAS Number
2445259-99-2
Product Name Alternative
LY3434172
UNSPSC
12352203
Target
PD-1/PD-L1
Type
Inhibitory Antibodies
Related Pathways
Immunology/Inflammation
Applications
Cancer-programmed cell death
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/reozalimab.html
Purity
99.90
Solubility
10 mM in DMSO|H2O
Smiles
[Reozalimab]
Molecular Weight
(143.55 kDa)
References & Citations
[1]Pattabiraman, et al. Synthetic IL-7 and IL-7-anti-PD-1 antibody immunocytokines for cancer therapy. World Intellectual Property Organization, WO2023281484 A1 2023-01-12.|[2]Reozalimab. IMGT/mAb-DB.
Shipping Conditions
Dry Ice
Storage Conditions
Store at -80°C for 2 years
Scientific Category
Inhibitory Antibodies
Clinical Information
Phase 1
Available Sizes
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
TL320033V 500 µL Each
C14orf61 Human shRNA Lentiviral Particle (Locus ID 283580)
Sign In for Pricing
View Details 
